Last reviewed · How we verify
Dexmedetomidine low-dose
At a glance
| Generic name | Dexmedetomidine low-dose |
|---|---|
| Also known as | dexmedetomidine hydrochloride Injection |
| Sponsor | Fujian Provincial Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Awareness Neuraxial Versus General Anesthesia in Frail Patients Undergoing Laparoscopic or Robotic Abdominopelvic Surgery. (NA)
- Effect of Dexmedetomidine Dosage on Postoperative Delirium in Geriatric Orthopedic Surgery (PHASE2)
- Efficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks (PHASE1, PHASE2)
- Propofol-Only Versus Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging (PHASE4)
- Comparative Dose-Response of Intrathecal Dexmedetomidine for Post-Spinal Shivering (PHASE3)
- Low Dose Dexmedetomidine Versus Normal Saline in Multiple Fracture Ribs (PHASE3)
- COMPARISON OF OPIOID-FREE AND OPIOID-BASED ANESTHESIA TECHNIQUES ON qNOX INDEX IN ABDOMINAL SURGERY UNDER GENERAL ANESTHESIA (NA)
- Dexmedetomidine-Enhanced PCIA After Lobectomy in Nicotine-Dependent Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexmedetomidine low-dose CI brief — competitive landscape report
- Dexmedetomidine low-dose updates RSS · CI watch RSS
- Fujian Provincial Hospital portfolio CI